1,288 Shares in Elevance Health, Inc. $ELV Purchased by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,288 shares of the company’s stock, valued at approximately $501,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Choreo LLC lifted its position in shares of Elevance Health by 2.0% during the third quarter. Choreo LLC now owns 5,622 shares of the company’s stock worth $2,186,000 after purchasing an additional 108 shares in the last quarter. Interchange Capital Partners LLC boosted its stake in shares of Elevance Health by 10.4% in the third quarter. Interchange Capital Partners LLC now owns 692 shares of the company’s stock valued at $269,000 after purchasing an additional 65 shares during the period. Livelsberger Financial Advisory acquired a new position in shares of Elevance Health in the third quarter valued at approximately $120,000. D.A. Davidson & CO. grew its holdings in shares of Elevance Health by 2.7% in the third quarter. D.A. Davidson & CO. now owns 4,336 shares of the company’s stock valued at $1,686,000 after purchasing an additional 116 shares in the last quarter. Finally, North Dakota State Investment Board increased its stake in Elevance Health by 39.1% during the 3rd quarter. North Dakota State Investment Board now owns 9,203 shares of the company’s stock worth $3,578,000 after buying an additional 2,588 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the sale, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Raymond James Financial set a $450.00 target price on shares of Elevance Health in a report on Tuesday, July 7th. Leerink Partners boosted their price target on shares of Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Sanford C. Bernstein set a $488.00 price objective on Elevance Health in a research report on Thursday, July 16th. TD Cowen upped their price objective on Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a research report on Friday, October 23rd. Finally, Robert W. Baird increased their price objective on Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a research note on Thursday, October 22nd. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $456.48.

Elevance Health Trading Down 0.1%

NYSE ELV opened at $419.67 on Monday. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $450.69. The firm has a 50 day moving average of $410.62 and a two-hundred day moving average of $372.32. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $90.67 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.00 and a beta of 0.70.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The business had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company’s revenue was up .7% on a year-over-year basis. During the same period last year, the business earned $6.03 EPS. As a group, research analysts expect that Elevance Health, Inc. will post 29.18 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is currently 29.34%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.